Komori
Susmed (4263) · RiskWorsened

Dilution of Per-Share Value Through Exercise of Stock Acquisition Rights and Additional Share Issuances

First written in FY2023. 2 of 4 entries say "Worsened", first in FY2025. Latest entry: FY2026.

4entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023MitigatedFY2024WorsenedFY2025 – FY20262023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
Share Dilution from Issuance of Additional Shares and Stock Acquisition RightsA theme 95 companies write about · 95 as a headwind · 0 as a tailwind

Susmed moved to the "Worse" side of this theme in 2025, 4 years after the typical company in this theme (2021).

The whole theme swung hardest in 2017: 17 of 34 companies on the "Worse" side.

15 other companies' latest entry also says "Worsened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 95 companies compared. The sentences above are computed from all 95.
Full recordFilings, disclosures and news, newest first
  1. FY2026WorsenedAnnual report

    「As of the date of submission of this document, the potential number of shares underlying these stock acquisition rights was 851,700, equivalent to 5.0% of the total 16,868,100 issued shares.」

    The potential number of shares underlying stock acquisition rights increased from 743,400 to 851,700, while the ratio to total issued shares increased from 4.4% to 5.0%.
  2. FY2025WorsenedAnnual report

    「As of the date of filing this document, the number of potential shares represented by these stock acquisition rights was 743,400, equivalent to 4.4% of the total 16,822,700 issued shares.」

    The number of potential shares represented by stock acquisition rights increased from 686,500 reported for the previous fiscal year to 743,400, and the ratio to total issued shares rose from 4.1% to 4.4%.
  3. FY2024MitigatedAnnual report

    「As of the date of filing this document, the number of potential shares represented by these stock acquisition rights was 686,500, equivalent to 4.1% of the total 16,759,300 issued shares.」

    The ratio of potential shares represented by stock acquisition rights declined from 10.5% reported for the previous fiscal year to 4.1%.
  4. FY2023First statedAnnual report

    「As of the date of filing this document, the number of potential shares represented by these stock acquisition rights was 1,390,100, equivalent to 10.5% of the total 16,640,000 issued shares.」

    The company describes the potential dilution of equity value per share through the exercise of stock acquisition rights and the issuance of restricted shares, using the number and ratio of potential shares.
Moved together

"Persistent Negative Operating Cash Flow and Impairment of Company-Wide Assets" moved the same way as this thread, in the same document, in 2 of its 4 moves.

2★1
  1. ★This thread
  2. 1Persistent Negative Operating Cash Flow and Impairment of Company-Wide Assets2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Susmed's next results are scheduled for 2026-11-06. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Dilution of Per-Share Value Through Exercise of Stock Acquisition Rights and Additional Share Issuances | SUSMED,Inc. (4263) | Komori